2
项与 CD19/BCMA-CAR-T cells(Essen Biotech) 相关的临床试验T-cell Infusion Targeting BCMA and CD19 for Refractory/Relapsed Systemic Lupus Erythematosus (SLE) Patients With or Without Organs Involvement
This study is a preliminary investigation, with a single-group design, not randomized and transparent, focusing on treatment. Its purpose is to identify the highest dose of BH002 injection (CD19-BCMA CAR-T cells) that patients suffering from resistant systemic lupus erythematosus can tolerate.
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
This is an open, single-arm, clinical study to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) targeting BCMA or CD19 or both sequentially in the treatment of Relapsed/ Refractory Autoimmune Disease such as Sjogren's Syndrome or Systemic Lupus Erythematosus and other Autoimmune Disease.
100 项与 CD19/BCMA-CAR-T cells(Essen Biotech) 相关的临床结果
100 项与 CD19/BCMA-CAR-T cells(Essen Biotech) 相关的转化医学
100 项与 CD19/BCMA-CAR-T cells(Essen Biotech) 相关的专利(医药)
100 项与 CD19/BCMA-CAR-T cells(Essen Biotech) 相关的药物交易